Glaxo adds flesh to its oncology ambitions
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
